Analyzing Epidemiology in the News

Epidemiology in the News: Randomized Trials Although screening is an essential part of modern health care and treatment, there is evidence in research that there are few screening tests available in handling major diseases. The research shows that there isn't even a reduction in disease-specific deaths. The situation makes death a common occurrence in the circumstances. There was an assessment of 16 screening tests focusing on 9 main diseases that manifest death as a common outcome.

The research team found 98 Meta analyses and 45 random, but controlled trials that focused on deaths caused by specific diseases or just deaths that result from all causes. Reductions in deaths that come from specific diseases were significantly rare while all-cause mortality deaths were the rarest (OUP, 2015). The study used systematic review to systematically evaluate evidence from randomized controlled trials (RCTs) to determine whether screening reduces mortality arising from diseases that often cause death.

The study was conducted from three sources: United States Preventive Services Task Force (USPSTF), PubMed and Cochrane Database of Systematic Reviews. The selected studies were the most comprehensive i.e. the ones with more long-term follow-up included in trials. Trials that were included in the study met the follow-up time of not less than 5 years. After selecting the studies for use, the trials were conducted for a period of 6 months between January and June, 2014 (Saquib, Saquib & Ioannidis, 2015). There were only 19 randomized trials for 11 diseases, i.e.

cervical cancer, aortic aneurysm, colorectal cancer, hepatocellullar cancer, lung cancer, oral cancer, prostate cancer, breast cancer, canbreat cancer, type 2 and cardiovascular disease. It is shown by the authors that disease specific deaths have reduced only by 30% in the estimates. The reduction stands at 11% for all-cause mortality estimates from the randomized and controlled trials that were analyzed.

In the disease specific mortality findings, the evidence is backed up by observations from individualized controlled trials from four meta analyses, but not even one of the 6 meta-analyses that incorporated the estimates for all-cause mortality showed signs of a reduction in mortality (OUP, 2015). How the study benefited from the randomized trial design? Research specialists suggest that randomized trials should be a serious consideration on as-is basis that is determined by the disease in question.

They say that in such cases, screening is likely to produce results even for a number of other outcomes apart from mortality. The authors conclude that the level of expectations for reductions in mortality rates should be carefully toned down. They say that although screening is a common and, indeed, popular researchers should demand for evidence of its effectiveness. Using randomized trials shows that screening has been overused and even misused and has got in the way of routine processes without sufficient evaluation.

The trials show that mortality is only one of the outcomes. Patients may be inclined to favor screening tests that reduce the danger of critical morbidity (OUP, 2015). In the randomized controlled trials, participants are placed in two important groups. These constitute the control and intervention group. Randomizing makes sure that the characteristics bound to affect the relationship between outcome and intervention measures will be equal in all areas of study, thus minimizing the possibility of bias (Levin, 2007).

Lessons That Emerged from Randomization That Would Not Have Been Demonstrated The summary gives health care providers and policy makers an RCT synthesis regarding the benefits of screening. We hope that the information will come in handy, especially in the wake of recent controversies. Disease screening has been an important element in modern health care. There have been controversies surrounding several popular screening tests. For instance, breast cancer screening for women of ages between 40 to 49 and the screening for prostate cancer has.